key: cord-1022733-s2iri3fu authors: Gagliardi, Delia; Costamagna, Gianluca; Abati, Elena; Mauri, Eleonora; Brusa, Roberta; Scudeller, Luigia; Andreoli, Luca; Citterio, Gaia; Piccin, Eleonora; Magri, Francesca; Meneri, Megi; Velardo, Daniele; Sciacco, Monica; Bresolin, Nereo; Corti, Stefania; Comi, Giacomo Pietro title: Impact of COVID‐19 on the quality of life of patients with neuromuscular disorders in the Lombardy area, Italy date: 2021-08-03 journal: Muscle Nerve DOI: 10.1002/mus.27378 sha: 2669e67c3b7aa57ec4df549123c9efaccf8cec95 doc_id: 1022733 cord_uid: s2iri3fu INTRODUCTION:/AIMS: Patients with neuromuscular disorders (NMDs), including many elderly, immunosuppressed, and disabled individuals, may have been particularly affected during the coronavirus disease 2019 (COVID‐19) pandemic in Lombardy, a COVID‐19 high‐incidence area between February and May 2020. We aimed to evaluate the effects of the COVID‐19 pandemic on the quality of life (QoL) and perceived disease burden of this group of patients. METHODS: We conducted a cross‐sectional phone‐based survey study between June 1 and June 14, 2020, on a sample of 240 NMD patients followed at our clinic in Milan, Italy. We asked about perceived NMD burden and QoL before and during the COVID‐19 pandemic. We collected responses on access to outpatient care and ancillary services. We investigated the presence of symptoms suggestive of COVID‐19 infection and confirmed cases. RESULTS: We collected 205 responses: 53 patients (25.9%) reported a subjective worsening of the underlying NMD. QoL measures showed a significant worsening between pre and pandemic time frames (odds ratio, 2.14 95%; confidence interval, 1.82–2.51). Outpatient visits were postponed in more than half of cases (57.1%), with 104 patients (50.7%) experiencing a cancellation of scheduled diagnostic tests. 79 patients (38.5%) reported at least one symptom attributable to COVID‐19 infection. Among the 10 patients tested with nasopharyngeal swabs, 6 tested positive and 3 died from respiratory failure, including 2 patients on corticosteroid/ immunosuppressive therapy. DISCUSSION: The COVID‐19 pandemic affected QoL and limited access to outpatient care and ancillary services of NMD patients in Lombardy between February and May 2020. (NMDs), including many elderly, immunosuppressed, and disabled patients, represent a concern for neurologists during the coronavirus disease 2019 (COVID- 19) pandemic. In parallel, the crisis has forced the postponement of millions of visits and has prompted the rapid implementation of at-distance approaches. All these efforts have been critical to mitigating the burden of infection during the first phase of the pandemic, but they have had consequences on the quality of life (QoL) and well-being of patients who have been infected or have been required to practice strict preventative measures. [1] [2] [3] Although some articles on NMD patients and their management during the COVID-19 pandemic have been published, [4] [5] [6] issues regarding this subgroup remain unsolved. (1) Some patients with NMDs may be at higher risk to develop a severe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection due to the involvement of respiratory muscles and chronic use of immunosuppressive therapies, 7, 8 but definitive data on infected NMD patients are still lacking. 9 (2) The health crisis has forced the dismantling of traditional health care services, 10 the postponement of in-person visits, 11 and the rapid implementation of at-distance approaches, but its impact at a population level is still unclear. (3) National authorities have imposed strict preventive measures, including prolonged home isolation, with uncertain consequences on the QoL of individuals with chronic debilitating diseases. To answer these questions, we assessed the QoL and the burden of SARS-CoV-2 infection of NMDs patients followed up at our NMD Centre in Milan, Lombardy, one of the SARS-CoV-2 worst-hit regions worldwide. 12 Particularly, we aimed at evaluating whether and how the COVID-19 pandemic has affected patients' QoL and has had an impact on the provision of care following healthcare reorganization. Moreover, we have provided a detailed description of patients with a confirmed or suspected diagnosis of COVID-19, evaluating factors (eg, neuromuscular deficits, ongoing chronic treatment) potentially impacting the clinical course and the outcome of the infection. We conducted a cross-sectional phone-based survey study between June 1 and June 14, 2020, among a sample of patients followed up at our NMD clinic in Milan, Italy. We included patients with consecutive sampling. Participants were both new and follow-up NMD patients who attended the clinic consecutively between February 1, 2019, and May 31, 2020. Inclusion criteria were: age 18 y or older and resident in Lombardy. Exclusion criteria included an undiagnosed NMD. All participants provided informed consent. Demographics were obtained from our institutional electronic records according to local regulations. Ospedale Maggiore Policlinico approved the study. Patients were contacted between 9 am and 7 pm. Non-respondents were re-contacted up to three times within a week at different times of the day. In case of bedridden, tracheostomized, or severely cognitively impaired patients (five in total) caregivers were interviewed. All data used for analysis were aggregated to ensure patients' anonymity. The survey was divided into four sections (supplemental material): 1. Demographics and comorbidities: some data were retrieved from clinical records. 2. Perceived disease burden and QoL before the pandemic: improvement, stability or worsening of patients' perception of NMD compared to that before the pandemic (February 2020) was retrospectively assessed. Perceived QoL was assessed using a 5-point Likert-type scale focusing on six items: sleep, appetite, pain, mood, employment satisfaction, and social relationships. Likert-type scale grading ranged from 1 (low burden) to 5 (high burden). Age, sex, diagnosis, and disease duration were retrieved from the clinical records. Information on the use of immunosuppressants and steroid therapies were retrieved from the survey (question 10 to 13, supplemental material). Patients receiving oral steroids were on long-term therapy with low dose (≤7.5 mg prednisone equivalent a day) and medium-dose (>7.5 mg, but ≤30 mg prednisone equivalent a day) corticosteroids. 13 Patient functional status was assessed by asking about activities of daily living (ADLs) (bathing, personal hygiene, toileting, dressing, selffeeding, and transferring), respiratory support, presence of dysphagia, and ambulation (question 5 to 8, in the Supporting Information Material, which is available online). Mean ± SD are reported for continuous variables. Relative frequencies, percentages as well as medians with interquartile ranges (IQR) are presented for categorical variables. To assess the effect of the pandemic period on perceived disease burden and QoL items, we employed multilevel mixed ordinal regression models, with "patient" as random effect and "timing" as fixed effect; these models take into account within-patient correlation and do not require further adjustment of p-value. We fitted a cumulative model of items, thus estimating a common effect of the pandemic on perceived disease burden and on the underlying trait "QoL," and a model with timing interacting with individual items, to assess whether the pandemic had a different effect on some of the individual QoL items. The reference timing was February 2020. To explore potential differences in subgroups, further models were fitted adding an interaction term between timing and each subgroup. The association of clinical features (age, sex, disease duration, independent ambulation, respiratory support, dysphagia, inflammatory disease, and steroid and immunosuppressive therapy) with changes in perceived disease burden and QoL during the pandemic period was also assessed. Statistical analyses were performed using GraphPad (Prism) ver- We contacted 240 out of 350 patients followed at our neuromuscular center and received 205 phone responses, resulting in a response rate of 85%; 110 undiagnosed patients under investigation for a possible NMD condition were excluded from the survey. Three patients out of 205 had died from COVID-19 infection, and 1 patient was unable to perform the survey due to a language barrier, resulting in 201 complete responses. worsening for employment satisfaction and social relationships (Table 3) . No significant differences were found considering the various NMD subgroups (Table 4) . Age, sex, disease duration, independent ambulation, respiratory support, steroid, and immunosuppressive therapy did not significantly modify the impact on QoL (Table 4) Considering confirmed cases (Table 5) Based on our survey, we found that the SARS-CoV-2 pandemic in Italy had an overall negative impact on access to visits, ancillary services, and QoL of our NMD patients regarding social relationships, mood, employment satisfaction, sleep, appetite, and pain. As regards QoL, we observed a worsening in all the items evalu- Although an exacerbation of the underlying disease cannot be excluded in patient 1, our MG patient who recovered from the infection (patient 2) had milder symptoms and did not experience a flare of the underlying disease. The fatal outcome observed in patient 4, who suffered from oculopharyngeal muscular dystrophy (OPMD), was likely due to respiratory impairment and old age. Referring to immunosuppressive therapies, the need for therapy dosage reduction vs. discontinuation in NMD patients is uncertain 7 and large systematic studies on the outcome of infected immuno- QoL and disease burden of NMD patients in the past. 21, 22 With our survey, we showed that the COVID-19 pandemic impaired some aspects of QoL and affected access to outpatient care and ancillary services, with limited use of at-distance alternatives, of NMD patients in a COVID-19 high-incidence area. Given the possibility of cyclical outbreaks of the infection, it will be important to offer alternatives to in-person care, redefine access to ancillary services and provide new approaches to support patients with chronic NMDs and their caregivers. The authors thank Associazione Amici del Centro Dino Ferrari for its support. This study was funded by Italian Ministry of Health, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Ricerca Corrente 2020 to NB and GPC. Open Access Funding provided by Universita degli Studi di Milano within the CRUI-CARE Agreement. None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. The data that support the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0001-8460-938X Daniele Velardo https://orcid.org/0000-0003-1837-2788 Neuropsychiatric symptoms and quality of life in Spanish Alzheimer's disease patients during COVID-19 lockdown People with suspected COVID-19 symptoms were more likely depressed and had lower health-related quality of life: the potential benefit of health literacy The mental health consequences of COVID-19 and physical distancing: the need for prevention and early intervention COVID-19 and neuromuscular disorders COVID-19 in patients with myasthenia gravis Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French rare health care for Neuromuscular Diseases Network How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review The impact of SARS-Cov-2 pandemic on stroke care: a warning message Estimating the impact of COVID-19 pandemic on services provided by Italian neuromuscular centers: an Italian Association of Myology survey of the acute phase A view from the front line of the COVID-19 war Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology Impact of the COVID-19 pandemic on mental health and quality of life among local residents in Liaoning Province, China: a cross-sectional study Significant reduction of physical activity in patients with neuromuscular disease during COVID-19 pandemic: the long-term consequences of quarantine Amyotrophic lateral sclerosisfrontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria Amyotrophic lateral sclerosis patients' and caregivers' distress and loneliness during COVID-19 lockdown Risk factors for predicting mortality in elderly patients with COVID-19: a review of clinical data in China Myasthenic crisis in COVID-19 Impacts of immunosuppression and immunodeficiency on COVID-19: a systematic review and meta-analysis A new self-report quality of life questionnaire for children with neuromuscular disorders: presentation of the instrument, rationale for its development, and some preliminary results Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle Nerve Impact of COVID-19 on the quality of life of patients with neuromuscular disorders in the Lombardy area